Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
- DOI
- 10.1177/24755303261477021
- Published
- 2026 Aug 12
- Container
- Journal of psoriasis and psoriatic arthritis
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/24755303261477021,
title = {Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).},
author = {Strober B and Augustin M and Tada Y and Parnell Lafferty K and Krol Y and Skobelev E and Ibrahim F and Fakharzadeh S and Gniadecki R},
year = {2026},
journal = {Journal of psoriasis and psoriatic arthritis},
doi = {10.1177/24755303261477021},
url = {https://doi.org/10.1177/24755303261477021}
}RIS
TY - JOUR TI - Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). AU - Strober B AU - Augustin M AU - Tada Y AU - Parnell Lafferty K AU - Krol Y AU - Skobelev E AU - Ibrahim F AU - Fakharzadeh S AU - Gniadecki R PY - 2026 JO - Journal of psoriasis and psoriatic arthritis DO - 10.1177/24755303261477021 UR - https://doi.org/10.1177/24755303261477021 ER -
APA
B, S., M, A., Y, T., K, P. L., Y, K., E, S., F, I., S, F., & R, G. (2026). Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).. Journal of psoriasis and psoriatic arthritis. https://doi.org/10.1177/24755303261477021
Source records
- pubmed · retrieved 2026-09-25T20:31:16.665Z